$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000165495423012335 Filed on September 28, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$2.106M	$1.760M	$4.854M
YoY Change	142.16%	128.35%	230.53%
Cost Of Revenue	$0.00	$100.0K	$420.0K
YoY Change	-100.0%	14.26%	93.08%
Gross Profit	$2.106M	$1.660M	$4.440M
YoY Change	168.91%	142.97%	254.94%
Gross Profit Margin	100.0%	94.32%	91.48%
Selling, General & Admin	$3.200M	$5.070M	$15.29M
YoY Change	-8.79%	-20.13%	-7.4%
% of Gross Profit	151.96%	305.42%	344.39%
Research & Development	$5.015M	$7.410M	$22.63M
YoY Change	-16.8%	-0.35%	6.11%
% of Gross Profit	238.11%	446.39%	509.7%
Depreciation & Amortization	$90.00K	$80.00K	$290.0K
YoY Change	50.94%	88.55%	128.94%
% of Gross Profit	4.27%	4.82%	6.53%
Operating Expenses	$8.215M	$12.48M	$37.31M
YoY Change	-14.63%	-9.46%	-1.96%
Operating Profit	-$6.109M	-$10.82M	-$32.46M
YoY Change	-30.21%	-17.41%	-11.29%
Interest Expense	$10.88K	$100.0K	$20.01K
YoY Change	13.33%	-70.01%	-32.58%
% of Operating Profit
Other Income/Expense, Net	$220.5K		$242.0K
YoY Change	-55.66%		-37.97%
Pretax Income	-$5.890M	-$10.71M	-$32.22M
YoY Change	-28.65%	-16.12%	-11.0%
Income Tax		$0.00	$4.675M
% Of Pretax Income
Net Earnings	-$5.888M	-$10.71M	-$27.54M
YoY Change	-28.67%	-16.12%	-23.91%
Net Earnings / Revenue	-279.6%	-608.52%	-567.44%
Basic Earnings Per Share	-$0.43		-$2.21
Diluted Earnings Per Share	-$0.48	-$0.91	-$2.53
COMMON SHARES
Basic Shares Outstanding	11.95M shares	11.52M shares	10.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.500M	$11.00M	$11.00M
YoY Change	-74.05%	-63.26%	-63.26%
Cash & Equivalents	$5.525M	$10.98M	$8.000M
Short-Term Investments	$0.00	$3.000M	$3.000M
Other Short-Term Assets	$1.300M	$1.900M	$1.900M
YoY Change	-38.24%	-1.68%	-1.68%
Inventory	$1.598M	$526.0K	$500.0K
Prepaid Expenses
Receivables	$1.349M	$2.916M	$2.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.805M	$16.32M	$16.30M
YoY Change	-62.54%	-52.82%	-52.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$597.6K	$684.9K	$1.600M
YoY Change	-3.76%	27.0%	12.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K	$100.0K
YoY Change	0.0%	0.0%	75.69%
Total Long-Term Assets	$1.442M	$1.618M	$1.600M
YoY Change	-1.54%	9.71%	8.5%
TOTAL ASSETS
Total Short-Term Assets	$9.805M	$16.32M	$16.30M
Total Long-Term Assets	$1.442M	$1.618M	$1.600M
Total Assets	$11.25M	$17.94M	$17.90M
YoY Change	-59.31%	-50.27%	-50.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.270M	$4.304M	$4.300M
YoY Change	-39.87%	36.29%	36.18%
Accrued Expenses	$7.152M	$6.511M	$6.900M
YoY Change	16.93%	-5.3%	-4.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K	$100.0K
YoY Change	-2.21%	-0.91%	-0.91%
Total Short-Term Liabilities	$13.61M	$15.13M	$15.10M
YoY Change	-14.2%	-6.94%	-7.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$2.027M	$2.083M	$2.600M
YoY Change	-26.01%	-27.19%	-23.32%
Total Long-Term Liabilities	$2.027M	$2.083M	$2.600M
YoY Change	-26.01%	-27.19%	-26.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.61M	$15.13M	$15.10M
Total Long-Term Liabilities	$2.027M	$2.083M	$2.600M
Total Liabilities	$16.14M	$17.81M	$17.80M
YoY Change	-15.92%	-10.09%	-10.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$421.4M	-$415.5M
YoY Change	6.34%	7.1%
Common Stock	$119.5K	$116.6K
YoY Change	28.59%	25.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.889M	$134.1K	$100.0K
YoY Change
Total Liabilities & Shareholders Equity	$11.25M	$17.94M	$17.90M
YoY Change	-59.31%	-50.27%	-50.38%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$5.888M	-$10.71M	-$27.54M
YoY Change	-28.67%	-16.12%	-23.91%
Depreciation, Depletion And Amortization	$90.00K	$80.00K	$290.0K
YoY Change	50.94%	88.55%	128.94%
Cash From Operating Activities	-$5.906M	-$9.610M	-$28.42M
YoY Change	23782.55%	24.5%	-154904.45%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$50.00K	$433.9K
YoY Change	-100.0%	-234.73%	66.02%
Acquisitions
YoY Change
Other Investing Activities	$2.990M	-$2.990M	-$2.990M
YoY Change
Cash From Investing Activities	$2.993M	-$3.050M	-$3.427M
YoY Change	-2219.19%	8118.81%	1211.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$10.14M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$448.9K	1.010M	$9.896M
YoY Change	-105.23%	-4237.65%	-133.07%
NET CHANGE
Cash From Operating Activities	-$5.906M	-9.610M	-$28.42M
Cash From Investing Activities	$2.993M	-3.050M	-$3.427M
Cash From Financing Activities	$448.9K	1.010M	$9.896M
Net Change In Cash	-$2.465M	-11.65M	-$21.95M
YoY Change	-71.82%	49.74%	-27.24%
FREE CASH FLOW
Cash From Operating Activities	-$5.906M	-$9.610M	-$28.42M
Capital Expenditures	$0.00	$50.00K	$433.9K
Free Cash Flow	-$5.906M	-$9.660M	-$28.85M
YoY Change	-5169.91%	25.75%	11772.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	56463	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10975	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	8812	usd
CY2023	us-gaap	Lease Cost LeaseCost	111897	usd
CY2022	us-gaap	Lease Cost LeaseCost	65275	usd
CY2023	ptn	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	2.3
CY2022	ptn	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	2.6
CY2022	ptn	Weighted Average Remaining Lease Term Years Finance Lease WeightedAverageRemainingLeaseTermYearsFinanceLease	2.4
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0550	pure
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0529	pure
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	406319	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	410007	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	10975	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	8812	usd
CY2022	us-gaap	Finance Lease Impairment Loss FinanceLeaseImpairmentLoss	56463	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	309791	usd
CY2022Q2	ptn	Office Equipment OfficeEquipment	1229300	usd
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1177868	usd
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1038610	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1196706	usd
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	902038	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3603874	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3169948	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2918964	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2630634	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	684910	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539314	usd
CY2023Q2	ptn	Equipment Under Finance Leases EquipmentUnderFinanceLeases	309791	usd
CY2023Q2	us-gaap	Ground Leases Accumulated Amortization GroundLeasesAccumulatedAmortization	157385	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35331000	usd
CY2023Q2	ptn	Research And Development And Amt Tax Credits ResearchAndDevelopmentAndAmtTaxCredits	8094000	usd
CY2022Q2	ptn	Research And Development And Amt Tax Credits ResearchAndDevelopmentAndAmtTaxCredits	7171000	usd
CY2023Q2	ptn	Basis Difference In Foreign Tax Credits BasisDifferenceInForeignTaxCredits	583000	usd
CY2022Q2	ptn	Basis Difference In Foreign Tax Credits BasisDifferenceInForeignTaxCredits	583000	usd
CY2023Q2	ptn	Basis Differences In Fixed Assets And Other BasisDifferencesInFixedAssetsAndOther	2766000	usd
CY2022Q2	ptn	Basis Differences In Fixed Assets And Other BasisDifferencesInFixedAssetsAndOther	2778000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	51516000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45863000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51516000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45863000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000911216
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9270947	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11656714	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2022	ptn	Fractional Shares FractionalShares	0	shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-15543
CY2023	dei	Entity Registrant Name EntityRegistrantName	PALATIN TECHNOLOGIES, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4078884
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Cedar Brook Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
CY2023	dei	City Area Code CityAreaCode	609
CY2023	dei	Local Phone Number LocalPhoneNumber	495‑2200
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2023	dei	Trading Symbol TradingSymbol	PTN
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	25882442	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11946646	shares
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7989582	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29939154	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2992890	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2915760	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1780020	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	526000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	944471	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1897281	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1932454	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	16321513	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	34596099	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	684910	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539314	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	876101	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	878465	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2023Q2	us-gaap	Assets Assets	17939440	usd
CY2022Q2	us-gaap	Assets Assets	36070794	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4303527	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3157617	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6511059	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6875216	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	354052	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	371124	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	106392	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	100921	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3856800	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5754986	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15131830	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16259864	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	544323	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	529398	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	46014	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	152407	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2083200	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2861250	usd
CY2023Q2	us-gaap	Liabilities Liabilities	17805367	usd
CY2022Q2	us-gaap	Liabilities Liabilities	19802919	usd
CY2023Q2	ptn	Escrowed Proceeds EscrowedProceeds	0	usd
CY2022Q2	ptn	Escrowed Proceeds EscrowedProceeds	-15000000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11656714	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9270947	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	116567	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	92709	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	415553049	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	404168822	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-415535583	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-387993696	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	134073	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17939440	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36070794	usd
CY2023	ptn	Product Revenue Net ProductRevenueNet	4850678	usd
CY2022	ptn	Product Revenue Net ProductRevenueNet	1218457	usd
CY2023	ptn	License And Contract Revenue LicenseAndContractRevenue	3000	usd
CY2022	ptn	License And Contract Revenue LicenseAndContractRevenue	250000	usd
CY2023	us-gaap	Revenues Revenues	4853678	usd
CY2022	us-gaap	Revenues Revenues	1468457	usd
CY2023	ptn	Cost Of Products Sold CostOfProductsSold	418470	usd
CY2022	ptn	Cost Of Products Sold CostOfProductsSold	217529	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22630577	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21327434	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15290836	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16511942	usd
CY2023	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	1027322	usd
CY2022	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	37312561	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	38056905	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-32458883	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-36588448	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	691981	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	29963	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-429971	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	389868	usd
CY2023	us-gaap	Interest Expense InterestExpense	20013	usd
CY2022	us-gaap	Interest Expense InterestExpense	29682	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	241997	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	390149	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32216886	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36198299	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4674999	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27541887	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-36198299	usd
CY2023	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-2.53
CY2022	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-3.79
CY2023	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	10890159	shares
CY2022	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	9543762	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2505538	usd
CY2022	ptn	Issuance Of Redeemable Convertible Preferred Stock And Warrants Amount IssuanceOfRedeemableConvertiblePreferredStockAndWarrantsAmount	234443	usd
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-221311	usd
CY2022	ptn	Stock Issued During Period Value Issued For Warrants Exercises StockIssuedDuringPeriodValueIssuedForWarrantsExercises	280000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16132	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-36198299	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1410917	usd
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-146062	usd
CY2023	ptn	Redemption Of Convertible Series B Series C Preferred Stock Amount RedemptionOfConvertibleSeriesBSeriesCPreferredStockAmount	0	usd
CY2023	ptn	Sale Of Common Stock And Warrants Net Of Costs Amount SaleOfCommonStockAndWarrantsNetOfCostsAmount	10143152	usd
CY2023	ptn	Stock Issued During Period Value Issued For Warrants Exercises StockIssuedDuringPeriodValueIssuedForWarrantsExercises	78	usd
CY2023	ptn	Reverse Stock Split Fractional Shares Amount ReverseStockSplitFractionalSharesAmount	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27541887	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	134073	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-27541887	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-36198299	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	288331	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	126668	usd
CY2023	ptn	Decrease In Right Of Use Asset DecreaseInRightOfUseAsset	371339	usd
CY2022	ptn	Decrease In Right Of Use Asset DecreaseInRightOfUseAsset	359348	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	429971	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-389868	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	0	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	234443	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1410917	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2505538	usd
CY2023	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	-1027322	usd
CY2022	ptn	Gainloss On Purchase Commitment GainlossOnPurchaseCommitment	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1135740	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-199577	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	35173	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1127225	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	418471	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	217529	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1109541	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2572657	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-364157	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1077838	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-371122	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-351851	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2042516	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1004400	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28419001	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29922749	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2992890	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	433927	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261374	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3426817	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-261374	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	146062	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	221311	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10143152	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	100922	usd
CY2022	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	56463	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	78	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	280000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16132	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9896246	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18358	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-21949572	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-30165765	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29939154	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60104919	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7989582	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29939154	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	20013	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	29682	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-415535583	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27541887	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10982472	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15131830	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5789218	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	29740565	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Credit Risk</em> – Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and accounts receivable. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. Currently, product revenues and related accounts receivable are generated primarily from one specialty pharmacy.</p>
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	500000	usd
CY2017Q3	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	7500000	usd
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	92500000	usd
CY2023	ptn	Revenues Related To License And Contract RevenuesRelatedToLicenseAndContract	3000	usd
CY2022	ptn	Revenues Related To License And Contract RevenuesRelatedToLicenseAndContract	250000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4161377	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2851959	shares
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	356003	shares
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	363780	shares
CY2023	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	1027322	usd
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue And Customer Advances And Deposits IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits	4500000	usd
CY2017Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	5000000	usd
CY2017Q4	us-gaap	Officers Compensation OfficersCompensation	417500	usd
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	500000	usd
CY2017Q4	ptn	Taxexpenses taxexpenses	82500	usd
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	3000000	usd
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	37500000	usd
CY2023Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	141512	usd
CY2022Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	310573	usd
CY2023Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	342645	usd
CY2022Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	132413	usd
CY2023Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	816750	usd
CY2022Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	815750	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	596374	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	673718	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1897281	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1932454	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2808598	usd
CY2023Q2	ptn	Cash Equivalents Treasury Bill At Carrying Value CashEquivalentsTreasuryBillAtCarryingValue	2980620	usd
CY2023Q2	ptn	Marketable Securities Treasury Bill At Carrying Value MarketableSecuritiesTreasuryBillAtCarryingValue	2992890	usd
CY2023Q2	ptn	Total Carrying Value TotalCarryingValue	8782108	usd
CY2022Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	29740565	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	418471	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	526000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	944471	usd
CY2023	ptn	Description Of Office Space DescriptionOfOfficeSpace	The Company has operating leases for office and laboratory space, which expire on June 30, 2025 and October 31, 2026, respectively
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	291878	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	294293	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	114441	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	114418	usd
CY2023	ptn	Total Operating Lease Cost TotalOperatingLeaseCost	406319	usd
CY2022	ptn	Total Operating Lease Cost TotalOperatingLeaseCost	408711	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	100922	usd
CY2023	ptn	Weighted Average Remaining Lease Term Years Finance Lease WeightedAverageRemainingLeaseTermYearsFinanceLease	1.4
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0550	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0529	pure
CY2023	us-gaap	Finance Lease Impairment Loss FinanceLeaseImpairmentLoss	100922	usd
CY2023	ptn	Total Measurement Of Lease Liabilities TotalMeasurementOfLeaseLiabilities	518216	usd
CY2022	ptn	Total Measurement Of Lease Liabilities TotalMeasurementOfLeaseLiabilities	475282	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	368975	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	111899	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	46625	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	6118	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	152406	usd
CY2023Q2	ptn	Office Equipment OfficeEquipment	1229300	usd
CY2023Q2	ptn	Clinical Study Costs ClinicalStudyCosts	2960126	usd
CY2022Q2	ptn	Clinical Study Costs ClinicalStudyCosts	3944798	usd
CY2023Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	121121	usd
CY2022Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	35172	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	339258	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	351257	usd
CY2023Q2	ptn	Personal Cost PersonalCost	1563847	usd
CY2022Q2	ptn	Personal Cost PersonalCost	1545896	usd
CY2023Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	1266653	usd
CY2022Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	840703	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	260054	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	157390	usd
CY2023Q2	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	6511059	usd
CY2022Q2	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	6875216	usd
CY2023	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	1027322	usd
CY2023Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	6896800	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3856800	usd
CY2023Q2	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	2083200	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5754986	usd
CY2022Q2	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	2861250	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	294431	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	220864	usd
CY2023	us-gaap	Proceeds From Grantors ProceedsFromGrantors	15000000	usd
CY2023	ptn	Voting Of Shares Description VotingOfSharesDescription	The holders of Series C Preferred Stock were entitled to 20,000 votes per share
CY2022Q4	ptn	Description Of Securities Purchase DescriptionOfSecuritiesPurchase	1,020,000 shares of the Company’s common stock, (ii) prefunded warrants (the “Pre-Funded Warrants”) to purchase up to 798,182 shares of the Company’s common stock, and (iii) common stock warrants (the “Common Warrants”) to purchase up to 1,818,182 shares of the Company’s common stock. Each share of common stock was offered with one accompanying Common Warrant with a combined offering price of $5.50. Each Pre-Funded Warrant was offered with one accompanying Common Warrant with a combined offering price of $5.4999
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2023	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	798182	shares
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	9109117	usd
CY2023	ptn	Description Of Commission DescriptionOfCommission	The Company pays Canaccord 3.0% of the gross proceeds as a commission
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	875299	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.00
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y2M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	310494	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11539	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	16.67
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1744	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	8548	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.79
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1163962	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.98
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y1M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	712310	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.30
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	274440	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.00
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	51232	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17.45
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1550600	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.27
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	537802	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1012798	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.05
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y4M24D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q2	ptn	Unvested Performance Based Stock Options Granted To Executive Officers And Other Employees UnvestedPerformanceBasedStockOptionsGrantedToExecutiveOfficersAndOtherEmployees	318813	shares
CY2023Q2	ptn	Unvested Performance Based Stock Options Granted UnvestedPerformanceBasedStockOptionsGranted	57999	shares
CY2020Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	87303	usd
CY2021Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	95167	usd
CY2022Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	60566	usd
CY2023Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	238838	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.032	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.656	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.691	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	ptn	Weighted Average Grant Date Fair Value Per Share WeightedAverageGrantDateFairValuePerShare	0.99
CY2022	ptn	Weighted Average Grant Date Fair Value Per Share WeightedAverageGrantDateFairValuePerShare	2.68
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	794735	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1563686	usd
CY2023Q2	ptn	Unrecognized Compensation Cost Unvested Option UnrecognizedCompensationCostUnvestedOption	1670986	usd
CY2023	ptn	Weighted Average Unrecogized Compensation Cost WeightedAverageUnrecogizedCompensationCost	P2Y7M6D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	649149	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	593629	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	425750	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	131352	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3312	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	6426	shares
CY2023	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-84062	shares
CY2022	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-69406	shares
CY2023	ptn	Fractional Shares FractionalShares	-4	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	987521	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	649149	shares
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	616182	usd
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	941852	usd
CY2023Q2	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Veste Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVesteOutstandingNumber	356003	shares
CY2023	ptn	Sale Value Of The Tax Benefits To Unaffiliated SaleValueOfTheTaxBenefitsToUnaffiliated	0.80	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4674999	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	155000000	usd
CY2023	us-gaap	Allowance For Loan And Lease Losses Loans Acquired AllowanceForLoanAndLeaseLossesLoansAcquired	5653000	usd
CY2022	us-gaap	Allowance For Loan And Lease Losses Loans Acquired AllowanceForLoanAndLeaseLossesLoansAcquired	3927000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40073000	usd

Files In Submission

Name	View Source	Status
ptn-20230630_cal.xml	Edgar Link	unprocessable
0001654954-23-012335-index-headers.html	Edgar Link	pending
0001654954-23-012335-index.html	Edgar Link	pending
0001654954-23-012335.txt	Edgar Link	pending
0001654954-23-012335-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20230630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ptn_10k.htm	Edgar Link	pending
ptn_10kimg26.jpg	Edgar Link	pending
ptn_10kimg28.jpg	Edgar Link	pending
ptn_ex1011.htm	Edgar Link	pending
ptn_ex211.htm	Edgar Link	pending
ptn_ex23.htm	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
ptn-20230630_def.xml	Edgar Link	unprocessable
ptn-20230630_pre.xml	Edgar Link	unprocessable
ptn-20230630_lab.xml	Edgar Link	unprocessable
ptn_10k_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2023 Q3 Form 10-K Financial Statement

#000165495423012335 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2023 Q3 Form 10-K Financial Statement

#000165495423012335 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn